Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDEFINE-HF finerenone trial in hospitalized heart failure with LVEF >=40%
2023-508581-15-00Phase 3Authorised
- Sponsor
- CPC Clinical Research
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised trial of finerenone in heart failure with preserved ejection fraction (HFpEF) and heart failure (HF) (2 arms), sponsored by CPC Clinical Research. Primary endpoint: Primary composite endpoint. Planned start Oct 2024; status: authorised.
02
Drugs
finerenone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure (HF)
Beyond the preview
Go deeper on 2023-508581-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508581-15-00.